EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment of an oral enterovirus 71 (EV71) infection model in immunocompetent mice for antiviral therapy evaluation

Yisha Ma iD, Dan Luo, Xianliang Ke, Xiaohui Song, Mengchan Hao, Jianjun Chen iD, Yuan Zhang iD

Journal of Virology · 23.06.2026 · 100 (6)

DOI: 10.1128/jvi.02068-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 23.06.2026. Verfasst von Yisha Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology and Biosafety, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, People's Republic of China. Hauptthemen laut MEDLINE: Enterovirus A, Human, Disease Models, Animal, Antiviral Agents, Enterovirus Infections. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province, Wuhan Medical Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enterovirus 71 (EV71) is one of the major pathogens responsible for hand-foot-and-mouth disease in children and is associated with severe neurological complications, including death. Despite the fact that EV71 naturally infects humans through the oral route, the absence of a simple and reliable oral infection model has significantly impeded investigations into its pathogenesis and the development of antiviral interventions. In this study, we established a robust oral EV71 infection model in widely used immunocompetent BALB/c mice, employing a clinical isolate devoid of adaptive mutations. Mice infected via the oral route developed disease progression and clinical, as well as pathological features that closely recapitulate those observed in human infection. We further identified marked differences in viral dissemination and host immune responses between oral and intraperitoneal inoculation, underscoring the importance of physiologically relevant oral infection models for elucidating EV71 pathogenesis. In addition, the anti-EV71 candidate drug rupintrivir showed reduced efficacy in the oral infection model compared with the intraperitoneal model. Notably, this oral model enables evaluation of therapies designed to block intestinal viral infection—a capability lacking in intraperitoneal models. Using this platform, we assessed an intestinal probiotic blockade therapy for the first time. Our findings demonstrate that the probiotic formulation effectively suppresses viral replication and alleviates pathological damage in the spleen, lungs, kidneys, and other organs, providing a scientific basis for developing probiotic-based therapeutic strategies against viral infections. IMPORTANCE The restricted host tropism of enterovirus 71 (EV71) has limited the development of animal models that accurately recapitulate human disease. Here, we demonstrate for the first time that the clinically isolated EV71-GZCII strain successfully infects 14-day-old immunocompetent BALB/c mice via oral gavage, establishing a physiologically relevant model that addresses this critical gap. Orally infected mice displayed distinct viral dissemination patterns and host immune responses compared with intraperitoneal models, highlighting the critical role of infection route in EV71 pathogenesis. Using this system, we evaluated the in vivo therapeutic efficacy of the 3C protease inhibitor rupintrivir and found that its apparent efficacy is strongly influenced by the route of infection. Furthermore, we employed this oral model to assess probiotic-based antiviral therapy, revealing effective suppression of viral replication and pathology. Unlike intraperitoneal systems, this model uniquely enables evaluation of intestinal interventions, providing a robust platform for EV71 research and therapy development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterovirus A, HumanDisease Models, AnimalAntiviral AgentsEnterovirus InfectionsHand, Foot and Mouth DiseaseAnimalsMice, Inbred BALB CMiceHumansAdministration, OralFemaleImmunocompetenceVirus ReplicationProbiotics

Stichwörter der Autor:innen

EV71antiviral drugsimmune responseimmunocompetent miceintestinal probiotic blockade therapyoral infectionvirus transmission in vivo

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • State Key Laboratory of Virology and Biosafety, Chinese Academy of Sciences Wuhan Institute of Virology, Wuhan, People's Republic of China.
  • University of Chinese Academy of Sciences, Beijing, People's Republic of China.
  • Department of Gastroenterology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  • Department of Obstetrics, Wuhan Children's Hospital, Wuhan Maternal and Child Healthcare Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.

ORCID-Profile: Yisha Ma, Jianjun Chen, Yuan Zhang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province
  • Wuhan Medical Research Project

Zitieren

APA

Ma, Y., Luo, D., Ke, X., Song, X., Hao, M., Chen, J., & Zhang, Y. (2026). Establishment of an oral enterovirus 71 (EV71) infection model in immunocompetent mice for antiviral therapy evaluation. Journal of Virology, 100(6). https://doi.org/10.1128/jvi.02068-25

Vancouver

Ma Y, Luo D, Ke X, Song X, Hao M, Chen J, et al. Establishment of an oral enterovirus 71 (EV71) infection model in immunocompetent mice for antiviral therapy evaluation. Journal of Virology. 2026;100(6). doi:10.1128/jvi.02068-25

BibTeX
@article{Ma2026,
  author = {Ma, Yisha and Luo, Dan and Ke, Xianliang and Song, Xiaohui and Hao, Mengchan and Chen, Jianjun and Zhang, Yuan},
  title = {Establishment of an oral enterovirus 71 (EV71) infection model in immunocompetent mice for antiviral therapy evaluation},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {6},
  doi = {10.1128/jvi.02068-25}
}
Kostenlos starten →